Kobayashi Pharmaceutical Co., Ltd. (4967.T) fair value

ACCE thesis

Kobayashi Pharmaceutical makes consumer health and personal care products in Japan, including Bleach (the toilet cleaner brand), Sarasa Clean gel pens, and a range of OTC drugs and supplements. The company's edge is brand strength in mass-market categories where repeat purchase is habitual, which supports a 50.7% gross margin. Revenue growth is slow at 1.8%, and the 2.3% operating margin and 0.8% ROE show that very little of that gross profit reaches shareholders today, so the case rests on margin recovery rather than top-line momentum. The stock trades at 331x trailing earnings but 30.3x forward, a gap that signals earnings are expected to rebound sharply from a depressed base. That rebound is the thing to test: a deeper look should focus on whether the recent cost and quality-control problems in its supplement business are contained, and whether operating margin can climb back toward historical levels.